Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

Similar articles for PubMed (Select 24938379)

1.

HIV-related NK/T-cell lymphoma in the brain relapsed during intensive chemotherapy but regressed after chemotherapy discontinuation: the importance of maintaining cellular immunity.

Nagahata Y, Kato A, Imai Y, Ishikawa T.

Int J Hematol. 2014 Oct;100(4):402-6. doi: 10.1007/s12185-014-1610-2. Epub 2014 Jun 18.

PMID:
24938379
2.

Functional restoration of human immunodeficiency virus and Epstein-Barr virus-specific CD8(+) T cells during highly active antiretroviral therapy is associated with an increase in CD4(+) T cells.

Kostense S, Otto SA, Knol GJ, Manting EH, Nanlohy NM, Jansen C, Lange JM, van Oers MH, Miedema F, van Baarle D.

Eur J Immunol. 2002 Apr;32(4):1080-9.

PMID:
11920575
3.
4.

Magnitude and complexity of rectal mucosa HIV-1-specific CD8+ T-cell responses during chronic infection reflect clinical status.

Critchfield JW, Young DH, Hayes TL, Braun JV, Garcia JC, Pollard RB, Shacklett BL.

PLoS One. 2008;3(10):e3577. doi: 10.1371/journal.pone.0003577. Epub 2008 Oct 30.

5.

NK/T-cell lymphoma associated with Epstein-Barr virus in a patient infected with human immunodeficiency virus: an autopsy case.

Oh SC, Choi CW, Kim BS, Shin SW, Kim YH, Lee JS, Kim MJ, Jung WY, Kim HK, Yeom BW, Kim IS, Kim JS.

Int J Hematol. 2004 Jun;79(5):480-3.

PMID:
15239400
6.

Dysfunctional Epstein-Barr virus (EBV)-specific CD8(+) T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hodgkin lymphoma.

van Baarle D, Hovenkamp E, Callan MF, Wolthers KC, Kostense S, Tan LC, Niesters HG, Osterhaus AD, McMichael AJ, van Oers MH, Miedema F.

Blood. 2001 Jul 1;98(1):146-55.

7.

Cytotoxic large T-cell lymphoma with fulminant clinical course, CD8+ and CD56- phenotype, and its relation to Epstein-Barr virus: a report of two cases.

Kagami Y, Sobue R, Ito N, Yatabe Y, Taji H, Suzuki R, Seto M, Ogura M, Suchi T, Morishima Y, Nakamura S.

Int J Hematol. 1999 Aug;70(2):105-11.

PMID:
10497849
8.

Profile of immunologic recovery in HIV-infected Ugandan adults after antiretroviral therapy.

Baker CA, Emenyonu N, Ssewanyana I, Jones NG, Elrefaei M, Nghania F, Nakiwala J, Andia I, Clark R, Martin J, Bangsberg DR, Cao H.

AIDS Res Hum Retroviruses. 2007 Jul;23(7):900-5.

PMID:
17678474
9.

Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size.

Jain V, Hartogensis W, Bacchetti P, Hunt PW, Hatano H, Sinclair E, Epling L, Lee TH, Busch MP, McCune JM, Pilcher CD, Hecht FM, Deeks SG.

J Infect Dis. 2013 Oct 15;208(8):1202-11. doi: 10.1093/infdis/jit311. Epub 2013 Jul 12.

10.

Reduction in CD8+ cell noncytotoxic anti-HIV activity in individuals receiving highly active antiretroviral therapy during primary infection.

Stranford SA, Ong JC, Martinez-Marino B, Busch M, Hecht FM, Kahn J, Levy JA.

Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):597-602. Epub 2001 Jan 2.

11.

Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA.

Goicoechea M, Smith DM, Liu L, May S, Tenorio AR, Ignacio CC, Landay A, Haubrich R.

J Infect Dis. 2006 Jul 1;194(1):29-37. Epub 2006 May 18.

12.

Epstein-Barr virus-positive T-cell lymphoma cells having chromosome 22q11.2 deletion: an autopsy report of DiGeorge syndrome.

Itoh S, Ohno T, Kakizaki S, Ichinohasama R.

Hum Pathol. 2011 Dec;42(12):2037-41. doi: 10.1016/j.humpath.2010.03.014. Epub 2011 Jun 17.

PMID:
21683977
13.

Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma.

Bihl F, Mosam A, Henry LN, Chisholm JV 3rd, Dollard S, Gumbi P, Cassol E, Page T, Mueller N, Kiepiela P, Martin JN, Coovadia HM, Scadden DT, Brander C.

AIDS. 2007 Jun 19;21(10):1245-52.

PMID:
17545700
14.

Natural killer-like T-cell lymphoma of the parotid in a patient infected with human immunodeficiency virus.

Cornfield DB, Papiez JS, Lynch JT, Rimsza LM.

Arch Pathol Lab Med. 2002 Jun;126(6):738-41.

PMID:
12033970
15.

Early impairment of CD8+ T cells immune response against Epstein-Barr virus (EBV) antigens associated with high level of circulating mononuclear EBV DNA load in HIV infection.

Legoff J, Amiel C, Calisonni O, Fromentin D, Rajoely B, Abuaf N, Tartour E, Rozenbaum W, Bélec L, Nicolas JC.

J Clin Immunol. 2004 Mar;24(2):125-34.

PMID:
15024179
16.

Primary extranodal nasal-type natural killer/T-cell lymphoma of the brain: a case report.

Kaluza V, Rao DS, Said JW, de Vos S.

Hum Pathol. 2006 Jun;37(6):769-72.

PMID:
16733220
17.

Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity.

Price DA, Scullard G, Oxenius A, Braganza R, Beddows SA, Kazmi S, Clarke JR, Johnson GE, Weber JN, Phillips RE.

J Virol. 2003 May;77(10):6041-9.

18.

CNK/T-cell brain lymphoma associated with Epstein-Barr virus in a patient with AIDS.

Cobo F, Talavera P, Busquier H, Concha A.

Neuropathology. 2007 Aug;27(4):396-402.

PMID:
17899696
19.
20.

Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.

Oxenius A, Price DA, Günthard HF, Dawson SJ, Fagard C, Perrin L, Fischer M, Weber R, Plana M, García F, Hirschel B, McLean A, Phillips RE.

Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13747-52. Epub 2002 Oct 7.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk